Capital Change Notice – Issue of ordinary shares

Capital Change Notice

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com


26 May 2022

Issue of ordinary shares

This notice is given under NZX Listing Rule 3.13.1 and relates to the issue of ordinary shares in
AFT Pharmaceuticals Limited under the AFT Pharmaceuticals Limited Long Term Incentive Plan.

Section 1: Issuer information
Name of issuer AFT Pharmaceuticals Limited
NZX ticker code AFT
Class of financial product Ordinary shares
ISIN (If unknown, check on NZX website) NZAFTE0001S4
Currency NZD
Section 2: Capital change details
Number issued 9,000
Nominal value (if any) Not applicable
Issue price per security 9,000 of the shares were issued at
$2.80 per share
Nature of the payment Not applicable
Amount paid up (if not in full) In full
Percentage of total class of Financial Products issued
(calculated on the number of Financial Products of the
Class, excluding any Treasury Stock, in existence)
0.01%
For an issue of Convertible Financial Products or
Options, the principal terms of Conversion
Not applicable
Reason for issue and specific authority for issue 9,000 shares were issued to an
employee exercising options under the
AFT Pharmaceuticals Limited Long
Term Incentive Plan
Total number of Financial Products of the Class after
the issue (excluding Treasury Stock) and the total
number of Financial Products of the Class held as
Treasury Stock after the issue.
104,759,760
Specific authority for the issue, including a reference
to the rule pursuant to which the issue is made
Directors’ resolution, Listing Rule 4.6
Terms or details of the issue (for example: restrictions,
escrow arrangements)
The ordinary shares issued rank pari
passu with the existing ordinary shares
Date of issue 26 May 2022

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

Section 3: Authority for this announcement and contact person
Name of person

authorised to make this
announcement
Malcolm Tubby
Contact person for this announcement Malcolm Tubby
Contact phone number +64 9 488 0232
Contact email address malcolm@aftpharm.com
Date of release through MAP

26 May 2022